Balance Sheet Details

9 Months Ended

Sep. 30, 2023

Balance Sheet Details

Balance Sheet Details

6. Balance Sheet Details

Property and Equipment

Property and equipment as of September 30, 2023 and December 31, 2022 consisted of the following:

	September 30, 2023		December 31, 2022
Laboratory and manufacturing equipment	$	16,317,000	$	10,007,000
Furniture and fixtures		817,000		817,000
Office and computer equipment		438,000		449,000
Leasehold improvements		3,447,000		3,447,000
Total		21,019,000		14,720,000
Less: accumulated depreciation and amortization		(11,769,000)		(11,103,000)
Property and equipment, net	$	9,250,000	$	3,617,000

Depreciation and amortization expense totaled $0.2 million for each of the three months ended September 30, 2023 and 2022, and $0.7 million and $0.6 million for the nine months ended September 30, 2023 and 2022, respectively. Construction in progress and fixed assets not in use were $9.3 million and $1.0 million as of September 30, 2023 and December 31, 2022, respectively, and are included in the laboratory and manufacturing equipment in the table above. These assets are not depreciated until they are placed in service.

Other receivables

Other receivables as of September 30, 2023 and December 31, 2022 consisted of the following:

	September 30, 2023		December 31, 2022
Tenant improvement allowance receivable (Note 12)	$	7,272,000	$	6,595,000
Awards receivable		1,225,000		1,936,000
	$	8,497,000	$	8,531,000

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities as of September 30, 2023 and December 31, 2022 consisted of the following:

	September 30, 2023		December 31, 2022
Accounts payable	$	3,772,000	$	1,678,000
Accrued clinical trial expenses		1,879,000		2,650,000
Other accrued expenses		1,049,000		1,706,000
	$	6,700,000	$	6,034,000